^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    topotecan

    i
    Other names: NK 211, NK-211, NK211, NSC 609699, SKF 104864
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    3d
    TREVI-OC-01: AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • torvutatug samrotecan (AZD5335)
    4d
    p38 inhibition restores chemosensitivity of tumor cells by disrupting oligomerized breast cancer resistance protein membrane trafficking. (PubMed, iScience)
    Cell lines with higher ABCG2 expression exhibited lower sensitivity to mitoxantrone, topotecan, and doxorubicin and diminished cytotoxic response. Mechanistically, p38 regulated the expression and membrane localization of oligomeric ABCG2, essential for its efflux activity. This study highlights p38 as a promising target to overcome ABCG2-mediated multidrug resistance and improve treatment outcomes for drug-resistant tumors.
    Journal
    |
    ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    doxorubicin hydrochloride • mitoxantrone • topotecan
    4d
    Mirvetuximab Soravtansine: Mechanism of Action, Clinical and Translational Science. (PubMed, Clin Transl Sci)
    Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate (ADC) composed of the DM4 payload conjugated to a folate receptor α (FRα)-targeting antibody via the cleavable sulfo-SPDB linker. The MIRV Phase 3 registrational trial (MIRASOL) showed superiority of MIRV vs. chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients with high (≥ 75%) FRα-expression PROC, showing an objective response rate of 42% versus 16%, a median progression-free survival of 5.6 versus 4.0 months, and an overall survival of 16.5 versus 12.8 months. Here, we briefly review MIRV mechanism of action, pharmacokinetics, pharmacodynamics, and key clinical efficacy and safety data.
    Review • Journal
    |
    FOLR1 ( Folate receptor alpha ) • PROC (Protein C, Inactivator Of Coagulation Factors Va And VIIIa)
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan
    7d
    REJOICE-Ovarian01: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=860, Recruiting, Daiichi Sankyo | Trial completion date: Dec 2029 --> Apr 2030
    Trial completion date • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    7d
    BEACON2: A Multi-Arm, Platform Trial For Relapsed Neuroblastoma (clinicaltrials.gov)
    P1/2, N=160, Recruiting, University of Birmingham
    New P1/2 trial
    |
    Avastin (bevacizumab) • irinotecan • topotecan • Qarziba (dinutuximab beta)
    12d
    Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma (clinicaltrials.gov)
    P2, N=406, Not yet recruiting, Milton S. Hershey Medical Center
    New P2 trial • Pan tumor
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • Iwilfin (eflornithine)
    15d
    Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=420, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    topotecan • alveltamig (ZG006)
    1m
    Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (clinicaltrials.gov)
    P1, N=15, Recruiting, C17 Council | Not yet recruiting --> Recruiting | Trial completion date: Sep 2032 --> Dec 2032 | Trial primary completion date: Sep 2030 --> Dec 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • temozolomide • tamoxifen • cytarabine • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • thiotepa • Neupogen (filgrastim) • celecoxib oral
    1m
    HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P3, N=468, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    paclitaxel • doxorubicin hydrochloride • topotecan • mocertatug rezetecan (GSK5733584)
    1m
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline
    New P3 trial • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    1m
    NCAPH promotes immune evasion via inhibiting PD-L1 protein degradation in head and neck squamous cell carcinoma. (PubMed, Cancer Lett)
    Notably, we demonstrated that NPIDP and topotecan suppress tumor immune evasion both in vitro and in vivo. In summary, our findings reveal the critical role of NCAPH in regulating tumor immune surveillance, suggesting that NCAPH could serve as a potential biomarker and therapeutic target for HNSCC in the future.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HIP1 (Huntingtin Interacting Protein 1)
    |
    topotecan